Clinical updates on EGFR/HER targeted agents in early-stage breast cancer

Clinical Breast Cancer

Volumn 10, Issue SUPPL. 1, 2010, Pages

  MacRinici, Valentina ^a   Romond, Edward ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

IGF 1R; Lapatinib; Monoclonal antibody; Neratinib; Pertuzumab; T DM1; Trastuzumab

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CARBOPLATIN PLUS DOCETAXEL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; EARLY CANCER; EARLY STAGE BREAST CANCER; GENE AMPLIFICATION; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; REVIEW;

EID: 77954442475     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.s.006     Document Type: Article

References (73)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792
4. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672 (Pubitemid 41464705)
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684
6. Jahanzeb M. Adjuvant Trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008; 8:324-333
7. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008; 8(suppl 4):S157-65.
8. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-8.
9. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001; 2:4-11.
10. Yu X, Sharma KD, Takahashi T, et al. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Biol Cell 2002; 13:2547-2557
11. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-1655
12. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3 kinase. Biochem J 1998; 333:757-763
13. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100:8933-8938
14. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200:290-297
15. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65:3781-3787
16. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11:793-814.
17. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-11128
18. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-1857.
19. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13:1198-1207
20. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:5838-5847
21. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132-4141
22. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-446
23. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER-2 positive breast cancer: An antibody-dependent cellular cytotoxicity mecha nism? Br J Cancer 2006; 94:259-267
24. Molina MA, Codony-Serat J, Albanel J, et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-4749
25. Le XF, Lammayot A, Gold D, et al. Genes affecting the cell cycle, growth, maintenance and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005; 280:2092-2104
26. Izumi Y, Xu L, di Tomasco E, et al. Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416:279-280
27. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15:7479-7491
28. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant MUC4-expressing breast cancer cell line. Cancer Res 2005; 65:473-482
29. Price-Schiavi SA, Jepson S, Li P, et al. Rat MUC-4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002; 99:783-791
30. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-2963
31. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-127
32. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12:395-402.
33. Gianni L, Goldhirsch A, Gelber R, et al. Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast 2009; 18(suppl.1):S11.
34. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B31 adjuvant chemotherapy with/without trastuzumab in patient with HER2-positive breast cancer. J Clin Oncol 2007; 25(18 suppl):6s (abstract 512)
35. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract LBA 80.
36. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Cancer Res 2009; 69(suppl):500S (abstract 62).
37. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009; 27:5685-5692
38. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27:6129-6134
39. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9:923-930
40. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26:5697-5704
41. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27:5700-5706
42. Black D, Younger J, Martei Y, et al. Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 2006; 100 (suppl):S92 (abstract 2037).
43. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27:5693-5699
44. Rodrigues MJ, Wassermann J, Albges-Sauvin L, et al. Treatment of node-negative infra-centrimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol 2009; 27 (suppl):10s (abstract 517).
45. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.I. 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed: January 8, 2010.
46. Leyland-Jones B. Human epidermal growth factor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27:5278-5286
47. Bria E, Cuppone F, Fournier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231-239
48. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145
49. Sukov WR, Miller DV, Dueck AC, et al. Benefit of adjuvant trastuzumab in breast cancer patient with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009; 27 (suppl):15s (abstract 520)
50. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358:1409-1411
51. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26:2999-3005.
52. Geyer CE, Martin A, Newstat B, et al. Lapatinib plus capecitabine in HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743
53. Tykerb evaluation after chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00374322?term=TEACH&rank=6. Accessed: January 8, 2010.
54. Blackwell KL, Burshtein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-1130
55. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimization). BIG 2-06/N063D. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00490139? term=ALTTO&rank=2. Accessed: January 8, 2010.
56. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
57. Wedam S, Low J, Yang S, et al. Antiangiogenic and antitumor effects of Bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777
58. Kallergi G, Markomanolaki H, Giannoukaraki V, et al. Hypoxia-inducible factor-1 and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009; 11:R84.
59. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
60. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; published ahead of print on May 24, 2010 as 10.1200/JCO. 2008.21.6457.
61. ClinicalTrials.gov [Web site]. BETH study. Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00625898?term=BETH&rank=1. Accessed: January 8, 2010.
62. Smith JW, Buyse M, Rastogi P, et al. Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer or as adjuvant therapy for HER2-positie pathologic stage III breast cancer: A phase II trial of the NSABP Foundation Research Group. J Clin Oncol 2009; 27(suppl):15s (abstract 580).
63. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patient with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at: The 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 31.
64. Gianni L, Eiermann W, Pusztai L, et al. Biomarkers as potential predictors of pathologic complete response in the NOAH trial of neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. J Clin Oncol 2008; 26(suppl):8s (abstract 504).
65. Dominici LS, Gonzalez VM, Buzdar AU, et al. Eradication of axillary lymph node metastases occurs in 74% of patients receiving neoadjuvant chemotherapy with concurrent trastuzumab for HER2 positive breast cancer. Cancer Res 2009; 69(suppl):566s (abstract 1086).
66. Nahta R, Hung MC, Esteva FJ. The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343-2346
67. Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase II multicenter trial of pertuzumab, a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab in patients with HER2 positive metastatic breast cancer which has progressed during treatment with trastuzumab. J Clin Oncol 2007; 25(18 suppl):33s (abstract 1004).
68. Burstein HJ, Sun Y, Tan AR, et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. Cancer Res 2009; 69(suppl):72s (abstract 37).
69. ClinicalTrials.gov [Web site]. Study evaluating the effects of neratinib in women with early stage breast cancer (ExteNET). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00878709?term=Neratinib&rank=3. Accessed: January 8, 2010.
70. Vogel CL, Burris HA, Limentani S, et al. A phage II study of trastuzumab-DM1, a HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer: Final results. J Clin Oncol 2009; 27(suppl):15s (abstract 1017).
71. Krop I, LoRusso P, Miller K, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib and trastuzumab. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 710.
72. Disis M, Wallace D, Gooley T, et al. Concurrent Trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685-4692
73. Peoples GE, Perez SA, Clifton GT, et al. Interim analysis of a randomized phase II study of the novel li-Key hybrid HER2/neu peptide (AE37) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 3183.